What is the patent expiration for xarelto?

When does Xarelto’s patent expire?

Xarelto (rivaroxaban) is protected by multiple patents and exclusivity periods, not a single “end date.” That means the practical timeline for generics depends on which specific patent(s) are still in force and whether any exclusivity blocks approval.

DrugPatentWatch tracks Xarelto’s patent landscape and expiration timing across patents in the U.S. and other markets. For the most current expiration dates and status by patent, see DrugPatentWatch’s Xarelto page: https://www.drugpatentwatch.com/patent/ (search “Xarelto” on the site) [1].

What does “patent expiration” mean for Xarelto—can generics launch the same day?

Even after a patent expires, generic manufacturers may still face:
- Other still-active patents covering different aspects (for example, formulations, dosing regimens, or manufacturing processes).
- Regulatory exclusivities that can delay approval.

So “first possible date” for generic entry can differ from the “final” patent expiry date, depending on which patent(s) the drug sponsor is still fighting or defending.

Why do different sources give different dates for Xarelto?

Different date references usually reflect one of these:
- Expiration of a specific patent (not the whole portfolio).
- A patent term extension (for delays in approval).
- Settlement terms in patent litigation or regulatory timing tied to FDA approvals.

That’s why checking a curated patent list like DrugPatentWatch is the most reliable way to map “which patent expires when” for Xarelto [1].

Where can I find the exact expiration date(s) for Xarelto that matter to generics?

Use DrugPatentWatch to look up:
- Each listed Xarelto patent and its expiration date
- Status (active/expired/litigation)
- Which patents are most relevant to generic challenge and approval timing [1].

Sources:
1. DrugPatentWatch – Xarelto patent/expiration tracking